Medical imaging
Positron-emission tomography (PET) is a functional imaging method that maps biochemical activity by detecting pairs of gamma rays produced when injected radioactive tracers emit positrons. Unlike mainly anatomical techniques such as computed tomography, PET can show altered metabolism, receptor binding, blood flow, or other molecular processes before structural changes become visible. It is used particularly in oncology, neurology, and cardiology, most often as PET/CT and less often as PET/MRI.
PET records paired photons from positron annihilation to reconstruct the distribution of a radiotracer inside the body. A positron is the antimatter counterpart of an electron; after traveling a short distance through tissue, it meets an electron and the two annihilate, producing two 511-keV photons moving in nearly opposite directions. Detector rings register photons arriving within a narrow coincidence interval, defining a probable line between the interactions. Many such measurements are reconstructed into cross-sectional images.
The resulting signal reflects tracer concentration and kinetics rather than anatomy alone. Corrections for photon attenuation, random coincidences, scatter, detector sensitivity, and patient motion improve quantitative accuracy. Modern scanners commonly combine PET with CT, whose x-ray data provide anatomical localization and attenuation correction; PET/MRI combines molecular imaging with soft-tissue contrast while reducing ionizing radiation from the anatomical component.1
PET’s clinical value comes from choosing a tracer that represents a biological process. 18F-fluorodeoxyglucose (FDG), a glucose analogue, accumulates in many tumors and in tissues with high glucose use, making it central to cancer staging, treatment assessment, and recurrence evaluation.2 FDG also highlights normal brain activity, inflammation, and infection, so increased uptake is not synonymous with cancer.
Other tracers measure different targets, including myocardial perfusion and viability, amyloid or tau pathology in selected neurological assessments, and prostate-specific membrane antigen expression in prostate cancer. In neurology, PET can assist evaluation of dementia patterns, epilepsy, and movement disorders; in cardiology, it can assess perfusion and living myocardium. Interpretation requires clinical context because uptake varies with blood glucose, recent activity, medications, timing, and technical conditions.
A PET examination usually involves preparation, intravenous tracer injection, a quiet uptake period, and scanning while the patient remains still. For FDG studies, fasting and control of blood glucose are commonly required; protocols differ according to the tracer and clinical question.1 The radioactive material decays relatively quickly, and the administered activity is selected to balance image quality with radiation exposure.
PET can reveal disease biology throughout the body in one examination, but it has limited spatial resolution compared with CT or MRI and may produce false-positive or false-negative findings. Inflammation, healing, infection, muscular activity, and some indolent tumors can alter FDG uptake. Pregnancy, diabetes, inability to remain still, renal considerations for accompanying contrast agents, and incidental findings may affect safety or interpretation. PET is therefore ordinarily interpreted alongside history, examination, laboratory data, and structural imaging.
Modern PET grew from early coincidence-detection research in nuclear physics and medical imaging during the mid-20th century, followed by the development of ring detectors, tomographic reconstruction, and short-lived medical radionuclides. Its expansion depended on cyclotrons, radiochemistry, and automated synthesis systems capable of producing tracers close to the point of use. The technique is consequently shaped as much by logistics and regulation as by scanner design.
Less familiar applications include research tracers for neurotransmitter transporters, immune-cell activity, hypoxia, and specific cancer receptors. PET can also measure dynamic tracer behavior over time rather than merely produce a static uptake image, allowing estimates of blood flow or metabolic rates. A practical edge case is the short half-life of many radionuclides: 18F is comparatively convenient because its half-life is about 110 minutes, whereas very short-lived isotopes require an on-site or nearby production facility. These constraints influence which tracers are available in different regions.3
Radiation dose, preparation, tracer selection, and interpretation depend on the individual examination and local clinical protocol.
Help improve the encyclopedia. Reports go straight to the site manager.